Incyte Corporation INCY announced results from a 12-week,
placebo-controlled, dose-escalation Phase II proof-of-concept clinical
trial involving 60 patients with active rheumatoid arthritis for its
proprietary oral JAK1 inhibitor. These results were presented today at
the 2013 American College of Rheumatology / Association of Rheumatology
Health Professionals (ACR/ARHP) Annual Scientific Meeting being held in
San Diego, CA, from Oct. 25 to 30, 2013.
“Along with our recently presented data with INCB39110 in psoriasis,
results from this study in rheumatoid arthritis demonstrate the
potential of JAK1 inhibition in inflammatory indications,” stated
Richard S. Levy, Incyte's Executive Vice President and Chief Drug
Development and Medical Officer.
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in